Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong near-term catalyst stack: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on 2026-04-30/05-01, Q1 2026 product revenue rose 57% YoY to $191.2M, NDA submitted for AXS-12, SUNOSI patent settlement extended protection, and the stock is up about 33% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Narrowing cash burn ⢠Rising leverage ⢠Negative profitability AXSM's improving losses and strong 94% gross margins are outweighed by continued cash burn, equity-financing dependence, rising leverage, and demanding valuationâfavor caution.
Price Behavior
Key Price Behavior Insights: ⢠Stalled rebound ⢠Weak momentum ⢠Key support Support Level: $198.00â$203.00 Resistance Level: $210.00, then $220.00â$221.00 AXSM is cautiously neutral-to-bearish over the last month, with a stalled rebound below $210 and downside risk if $198â203 support breaks.
Sentiment & News
Key News Insights: ⢠AUVELITY Growth ⢠Pipeline Expansion ⢠Profitability Risk Axsome's strong AUVELITY-led growth and pipeline progress support momentum, but ongoing losses, revenue miss, and insider selling temper the outlook.
AI Summary
AXSM is evolving into a high-growth specialty pharma led by AUVELITY, but its ~83% revenue concentration, ongoing cash burn, and premium valuation mean investors should require sustained revenue beats and clear progress toward self-funded profitability before adding aggressively.
Description
Axsome Therapeutics is a U.S.-based biopharmaceutical company developing treatments for central nervous system disorders. Its late-stage pipeline includes a depression candidate (AXS-05) with additional trials in Alzheimer's-related agitation and prior smoking cessation data, a migraine treatment that completed Phase III testing (AXS-07), and Phase III programs for narcolepsy (AXS-12) and fibromyalgia (AXS-14). The company has a research collaboration with Duke University and was founded in 2012 in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 5 | May 12 | AXSM | Axsome Therapeutics, Inc. | Strong near-term catalyst stack: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on 2026-04-30/05-01, Q1 2026 product revenue rose 57% YoY to $191.2M, NDA submitted for AXS-12, SUNOSI patent settlement extended protection, and the stock is up about 33% over 21 trading days. | Closed | +0.4% |
| Jan 1 | Jan 8 | AXSM | Axsome Therapeutics, Inc. | Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation. | Closed | -8.3% |